Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.
De Vos, Martine; Dhooghe, Barbara; Vermeire, Severineet al.
2018 • In United European Gastroenterology Journal, 6 (3), p. 439-445
Efficacy of vedolizumab for induction of clinical response and remission in...inflammatory bowel disease who failed at least two TNF antagonists_UEGJ_PPA.doc
United European Gastroenterology Journal
2018.
! Author(s) 2017
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
journals.sagepub.com/home/ueg
All documents in ORBi are protected by a user license.
[en] Background: Vedolizumab is a recently available monoclonal antibody targeting alpha4beta7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). Objective: The objective of this article is to evaluate the efficacy of vedolizumab induction therapy in anti-TNF-refractory/intolerant UC and CD patients in real life. Methods: A cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April-September 2015). Rates of clinical response and remission were retrospectively evaluated at Week 10 for UC and Week 14 for CD using the physician's global assessment (PGA), Mayo score and Harvey Bradshaw index (HBI) or Crohn's disease activity score (CDAI) scores. Results: Eighty-four patients (29 UC, 55 CD) had sufficient data for analysis. For UC patients, clinical response was observed in 76% based on PGA and 59% based on the Mayo score. The corresponding percentages for CD patients were 80% for PGA and 65% for HBI/CDAI. Clinical remission rates were 10% and 40% for UC and CD, respectively. Steroid-free remission was observed in respectively 10% and 35%. Globally, corticosteroids were stopped in 14 out of 48 patients (29%). No new safety signals were reported. Conclusion: Up to 70% TNF-refractory/intolerant UC and CD patients achieved a clinical response after 10 to 14 weeks of vedolizumab treatment in this real-life cohort.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
De Vos, Martine
Dhooghe, Barbara
Vermeire, Severine
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.
Allez M, Karmiris K, Louis E, Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355–366.
Krupka N, Baumgart DC. Designing biologic selectivity for inflammatory bowel disease—role of vedolizumab. Drug Des Devel Ther 2014; 9: 147–154.
Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel disease. Therap Adv Gastroenterol 2015; 8: 66–82.
Soler D, Chapman T, Yang LL, The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330: 864–875.
Feagan BG, Rutgeerts P, Sands BE, GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699–710.
Sandborn WJ, Feagan BG, Rutgeerts P, GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711–721.
Sands BE, Feagan BG, Rutgeerts P, Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618–627.
Colombel JF, Sands BE, Rutgeerts P, The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017; 66: 839–851.
Ha C, Ullman TA, Siegel CA, Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012; 10: 1002–1007.
Silverberg MS, Satsangi J, Ahmad T, Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Suppl A): 5–36.
Rutgeerts P, Sandborn WJ, Feagan BG, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–2476.
Lewis JD, Chuai S, Nessel L, Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 1660–1666.
Best WR, Becktel JM, Singleton JW, Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 439–444.
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980; 1: 514–514.
Baumgart DC, Bokemeyer B, Drabik A, Vedolizumab induction therapy for inflammatory bowel disease in clinical practice—a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016; 43: 1090–1102.
Amiot A, Grimaud JC, Peyrin-Biroulet L, Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2016; 14: 1593–1601.
Shelton E, Allegretti JR, Stevens B, Efficacy of vedolizumab as induction therapy in refractory IBD patients: A multicenter cohort. Inflamm Bowel Dis 2015; 21: 2879–2885.
Vivio EE, Kanuri N, Gilbertsen JJ, Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice. J Crohns Colitis 2016; 10: 402–409.
Dulai PS, Singh S, Jiang X, The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: Results from the US VICTORY Consortium. Am J Gastroenterol 2016; 111: 1147–1155.
Eriksson C, Marsal J, Bergemalm D, Long-term effectiveness of vedolizumab in inflammatory bowel disease: A national study based on the Swedish National Quality Registry for Inflammatory Bowel disease (SWIBREG). Scand J Gastroenterol 2017; 52: 722–729.
